Get started
Author

A. Plich

Observed names: A Plich, Adam Plich, Plich, Adam
OpenAlex ID: A5025404282
The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries
2016 · A. Lewis, S. Torvinen, et al. · BMC Health Services Research · 104
PDF
A review of the value of innovation in inhalers for COPD and asthma
2015 · Johann Christian Virchow, Cezmi A. Akdis, et al. · Journal of Market Access & Health Policy · 38
PDF
Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
2017 · Natalia Hawken, Saku Torvinen, et al. · BMC Pulmonary Medicine · 28
PDF
Budesonide + formoterol delivered via Spiromax® for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler®
2017 · A. Lewis, S. Torvinen, et al. · Respiratory Medicine · 12
PDF
Clinical And Economic Burden Of Asthma And Chronic Obstructive Pulmonary Disease In The Uk: Impact Of Critical Inhaler Errors With Inhaled Corticosteroid + Long-Acting Beta Agonist Fixed-Dose Combinations
2014 · A. Lewis, M. Blackney, et al. · Value in Health · 5
PDF
The Budget Impact Of Duoresp® Spiromax® Compared With Commonly Prescribed Dry Powder Inhalers For The Management Of Asthma And Chronic Obstructive Pulmonary Disease In Italy: Estimated Impact Of Inhalation Technique
2015 · S Torvinen, J Nicolai, et al. · Value in Health · 4
PDF
Identification of Dry Powder Inhaler Attributes, and their Relative Importance to Asthma and Chronic Obstructive Pulmonary Disease Patients, to Inform a Discrete Choice Experiment
2014 · N.A. Hawken, S. Aballéa, et al. · Value in Health · 4
PHP31 The Economic Impact of Switches of Prescription Drugs to the Over-the-Counter Status (Rx-to-OTC): A Systematic Literature Review
2011 · S.M. Karray, A. Plich, et al. · Value in Health · 4
The Potential For Improved Inhalation Technique With Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Commonly Prescribed Dry Powder Inhalers For The Management Of Asthma And Chronic Obstructive Pulmonary Disease In Spain: Estimated Impact On Number And Cost Of Unscheduled Healthcare Events
2015 · A Lewis, M Blackney, et al. · Value in Health · 3
PDF
Clinical And Economic Burden Of Asthma And Chronic Obstructive Pulmonary Disease (Copd) In Poland: Estimated Impact Of Poor Inhalation Technique With Inhaled Corticosteroid And Long-Acting Beta Agonist Fixed-Dose Combinations
2015 · P Bijos, J Kaczynski, et al. · Value in Health · 3
The Budget Impact of Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Symbicort® Turbohaler® for the Management of Asthma and Chronic Obstructive Pulmonary Disease in the United Kingdom: Impact on Health Care Costs and Inhalation Technique
2014 · A. Lewis, M. Blackney, et al. · Value in Health · 3
The Potential Societal Cost Benefits of Improved Inhalation Technique With Duoresp® Spiromax® (Budesonide + Formoterol Fumarate Dihydrate) Compared With Symbicort® Turbuhaler® for the Management of Asthma and Chronic Obstructive Pulmonary Disease in Sweden
2014 · A. Lewis, M. Blackney, et al. · Value in Health · 3
PDF
Comparative Effectiveness Analysis Of Mab In Asthma: The Importance Of Exacerbation Definition
2015 · S Torvinen, C Rémuzat, et al. · Value in Health · 1
Biosimilars Entry And Price Development In Europe
2015 · E Dacheva, A Plich, et al. · Value in Health · 1
Preferences for Dry Powder Inhaler Attributes Among Patients With Asthma and Chronic Obstructive Pulmonary Disease From Five European Countries
2015 · NA Hawken, I Amri, et al. · Value in Health · 1
Glatiramer Acetate 40 Mg/Ml Three Times A Week for The Treatment of Relapsing Forms of Multiple Sclerosis: Potential Cost Benefits of A Regimen With Infrequent Injections Which May Minimise Switching to The Newly-Introduced First-Line and Second-Line Disease Modifying Therapies
2015 · L Garcia Bujalance, M Kelly, et al. · Value in Health · 1
Estimation of Potential Cost Savings Associated With Reduced Rates of Cardiovascular Hospitalization Among Atrial Fibrillation/Flutter Patients Treated With Dronedarone in the ATHENA Trial
2013 · Matthew R. Reynolds, Jay Lin, et al. · American Journal of Therapeutics · 1
PP120 Health Technology Assessment Framework To Capture The Full Value Of Value Added Medicines
2017 · Mondher Toumi, Cecile Remuzat, et al. · International Journal of Technology Assessment in Health Care
PDF
Additional file 3: Table S3. of Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
2017 · Hawken, Natalia, Torvinen, Saku, et al. · Figshare
Additional file 4: Table S4. of Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
2017 · Hawken, Natalia, Torvinen, Saku, et al. · Figshare
Additional file 1: Table S1. of Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
2017 · Hawken, Natalia, Torvinen, Saku, et al. · Figshare
Additional file 2: Table S2. of Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
2017 · Hawken, Natalia, Torvinen, Saku, et al. · Figshare
The Potential to Improve Inhalation Technique in Patients with Asthma Or Copd By Switching From Symbicort® Turbuhaler® (Budesonide + Formoterol) to Duoresp® Spiromax®: Estimated Impact on The Number and Cost of Unscheduled Healthcare Events in Poland
2016 · A Watson, P Bijos, et al. · Value in Health
Additional file 1: of The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries
2016 · A. Lewis, S. Torvinen, et al. · Figshare
The Potential Societal Cost Benefits Of Increasing Patient Satisfaction By Using An Inhaler With Improved Features Compared To Spiriva® Handihaler® For The Management Of Chronic Obstructive Pulmonary Disease (Copd) In The Uk
2015 · JL Nicolai, S Torvinen, et al. · Value in Health
Works count: 43
Citation count: 216
H-index: 5
I10-index: 4
Year
Topic
Type